Acesso livre
Acesso livre

Medicina de Emergências

Prescrição de nirmatrelvir-ritonavir para Covid-19: como reconhecer e administrar as interações medicamentosas.

2 Mar, 2022 | 11:40h

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

Conteúdos relacionados:

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

Pfizer antiviral pills may be risky with other medications – NBC News

The New COVID-19 Pill, Paxlovid, Interacts with Many Medications: Cardiac Patients Take Note – The Skeptical Cardiologist

Diretriz atualizada da Joint British Diabetes Society for Inpatient Care | Tratamento da cetoacidose diabética em adultos.

1 Mar, 2022 | 15:41h

The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient Care

Diretriz | Plasmaférese e dosagem de glicocorticoides para pacientes com vasculite associada a ANCA.

28 Fev, 2022 | 13:35h

Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline – The BMJ

Ver também: The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis – The BMJ

 

Comentário no Twitter

 

Grandes queimados – Parte 1 | Epidemiologia, fisiopatologia e tratamento inicial.

25 Fev, 2022 | 14:12h

Major burns: Part 1. Epidemiology, pathophysiology and initial management – BJA Education

Estudo randomizado | Em sobreviventes comatosos de parada cardíaca, uma estratégia de supressão da atividade eletroencefalográfica (EEG) rítmica e periódica com uso de medicação anticonvulsivante não melhorou os desfechos neurológicos.

24 Fev, 2022 | 15:54h

Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

M-A | Acurácia diagnóstica de testes “point-of-care” nas infecções agudas de trato respiratório inferior adquiridas na comunidade.

24 Fev, 2022 | 13:37h

Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis – Clinical Microbiology and Infection

M-A | Características diagnósticas, tratamento e prognóstico do infarto do miocárdio tipo 2 em comparação ao tipo 1.

22 Fev, 2022 | 15:23h

Diagnostic features, management and prognosis of type 2 myocardial infarction compared to type 1 myocardial infarction: a systematic review and meta-analysis – BMJ Open

Síncope de início precoce e tardio: compreensão do mecanismo.

22 Fev, 2022 | 15:19h

Early and late-onset syncope: insight into mechanisms – European Heart Journal

 

Comentário no Twitter

 

Estudo randomizado | Em pacientes com Covid-19 leve a moderada e comorbidades, o tratamento com ivermectina não reduziu o risco de progressão da doença.

22 Fev, 2022 | 14:55h

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial – JAMA Internal Medicine

Comentários:

Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN

Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP

Conteúdos relacionados:

Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.

Long-term consequences of the misuse of ivermectin data.

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

Revisão | Tromboembolismo venoso associado a câncer.

22 Fev, 2022 | 14:37h

Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)

Infográfico: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (se o acesso a este link for pago, tente este)

Conteúdos relacionados:

NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.

ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer

Review: venous and arterial thromboembolism in patients with cancer.

Systematic Review: Does testing for cancer in people with unprovoked blood clots in the legs and lungs reduce cancer- and blood clot-related death and illness?

M-A: Extended thromboprophylaxis after hospital discharge for medically ill patients with cancer – Extended thromboprophylaxis is not associated with a reduced rate of venous thromboembolic events and is associated with increased risk of hemorrhage

Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.